These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 19438453)

  • 1. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity.
    Sartorius K; Emtestam L; Jemec GB; Lapins J
    Br J Dermatol; 2009 Oct; 161(4):831-9. PubMed ID: 19438453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interobserver variability of clinical scores in hidradenitis suppurativa is low.
    Sartorius K; Killasli H; Heilborn J; Jemec GB; Lapins J; Emtestam L
    Br J Dermatol; 2010 Jun; 162(6):1261-8. PubMed ID: 20184581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity.
    Canoui-Poitrine F; Revuz JE; Wolkenstein P; Viallette C; Gabison G; Pouget F; Poli F; Faye O; Bastuji-Garin S
    J Am Acad Dermatol; 2009 Jul; 61(1):51-7. PubMed ID: 19406505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychophysical aspects of hidradenitis suppurativa.
    Matusiak L; Bieniek A; Szepietowski JC
    Acta Derm Venereol; 2010 May; 90(3):264-8. PubMed ID: 20526543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depression in patients with hidradenitis suppurativa.
    Onderdijk AJ; van der Zee HH; Esmann S; Lophaven S; Dufour DN; Jemec GB; Boer J
    J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):473-8. PubMed ID: 22339940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.
    Mekkes JR; Bos JD
    Br J Dermatol; 2008 Feb; 158(2):370-4. PubMed ID: 18047504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa.
    Boer J; Jemec GB
    Clin Exp Dermatol; 2010 Jan; 35(1):36-40. PubMed ID: 19549239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept: effective in the management of hidradenitis suppurativa.
    Cusack C; Buckley C
    Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.
    Nazary M; van der Zee HH; Prens EP; Folkerts G; Boer J
    Eur J Pharmacol; 2011 Dec; 672(1-3):1-8. PubMed ID: 21930119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.
    Gener G; Canoui-Poitrine F; Revuz JE; Faye O; Poli F; Gabison G; Pouget F; Viallette C; Wolkenstein P; Bastuji-Garin S
    Dermatology; 2009; 219(2):148-54. PubMed ID: 19590173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa.
    Barth JH; Layton AM; Cunliffe WJ
    Br J Dermatol; 1996 Jun; 134(6):1057-9. PubMed ID: 8763424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness-to-pay and quality of life in patients with vitiligo.
    Radtke MA; Schäfer I; Gajur A; Langenbruch A; Augustin M
    Br J Dermatol; 2009 Jul; 161(1):134-9. PubMed ID: 19298268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic.
    Hahn HB; Melfi CA; Chuang TY; Lewis CW; Gonin R; Hanna MP; Farmer ER
    J Am Acad Dermatol; 2001 Jul; 45(1):44-8. PubMed ID: 11423833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity in patients with hidradenitis suppurativa.
    von der Werth JM; Jemec GB
    Br J Dermatol; 2001 Apr; 144(4):809-13. PubMed ID: 11298541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.
    Revuz JE; Canoui-Poitrine F; Wolkenstein P; Viallette C; Gabison G; Pouget F; Poli F; Faye O; Roujeau JC; Bonnelye G; Grob JJ; Bastuji-Garin S
    J Am Acad Dermatol; 2008 Oct; 59(4):596-601. PubMed ID: 18674845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
    Fardet L; Dupuy A; Kerob D; Levy A; Allez M; Begon E; Bachelez H; Morel P; Lebbé C
    J Am Acad Dermatol; 2007 Apr; 56(4):624-8. PubMed ID: 17240478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases.
    Wolkenstein P; Loundou A; Barrau K; Auquier P; Revuz J;
    J Am Acad Dermatol; 2007 Apr; 56(4):621-3. PubMed ID: 17097366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depression and anxiety among US adults: associations with body mass index.
    Zhao G; Ford ES; Dhingra S; Li C; Strine TW; Mokdad AH
    Int J Obes (Lond); 2009 Feb; 33(2):257-66. PubMed ID: 19125163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
    Zouboulis CC; Tzellos T; Kyrgidis A; Jemec GBE; Bechara FG; Giamarellos-Bourboulis EJ; Ingram JR; Kanni T; Karagiannidis I; Martorell A; Matusiak Ł; Pinter A; Prens EP; Presser D; Schneider-Burrus S; von Stebut E; Szepietowski JC; van der Zee HH; Wilden SM; Sabat R;
    Br J Dermatol; 2017 Nov; 177(5):1401-1409. PubMed ID: 28636793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.